Howard L Kaufman

List of Publications by Year
in descending order

159 papers	14,611 citations	57758 44 h-index	24258 110 g-index
164 all docs	164 docs citations	164 times ranked	13247 citing authors

#	Article	IF	Citations
1	Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma. Journal of Clinical Oncology, 2015, 33, 2780-2788.	1.6	1,988
2	Oncolytic viruses: a new class of immunotherapy drugs. Nature Reviews Drug Discovery, 2015, 14, 642-662.	46.4	1,055
3	Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. Lancet Oncology, The, 2016, 17, 1374-1385.	10.7	1,034
4	gp100 Peptide Vaccine and Interleukin-2 in Patients with Advanced Melanoma. New England Journal of Medicine, 2011, 364, 2119-2127.	27.0	809
5	Consensus guidelines for the definition, detection and interpretation of immunogenic cell death. , 2020, 8, e000337.		610
6	Phase II Clinical Trial of a Granulocyte-Macrophage Colony-Stimulating Factorâ€“Encoding, Second-Generation Oncolytic Herpesvirus in Patients With Unresectable Metastatic Melanoma. Journal of Clinical Oncology, 2009, 27, 5763-5771.	1.6	540
7	Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma. Journal of Clinical Oncology, 2018, 36, 1658-1667.	1.6	483
8	Local and Distant Immunity Induced by Intralesional Vaccination with an Oncolytic Herpes Virus Encoding GM-CSF in Patients with Stage IIIc and IV Melanoma. Annals of Surgical Oncology, 2010, 17, 718-730.	1.5	451
9	Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma. Journal of Clinical Oncology, 2016, 34, 2619-2626.	1.6	449
10	Integrating oncolytic viruses in combination cancer immunotherapy. Nature Reviews Immunology, 2018, 18, 498-513.	22.7	448
11	Characterization of CD4⁺CD25⁺ Regulatory T Cells in Patients Treated With High-Dose Interleukin-2 for Metastatic Melanoma or Renal Cell Carcinoma. Journal of Clinical Oncology, 2006, 24, 1169-1177.	1.6	330
12	Efficacy and Safety of First-line Avelumab Treatment in Patients With Stage IV Metastatic Merkel Cell Carcinoma. JAMA Oncology, 2018, 4, e180077.	7.1	304
13	Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after â‰¥1Âyear of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial. , 2018, 6, 7.		263
14	Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage IIIâ€“IV melanoma. , 2019, 7, 145.		261
15	Patterns of Clinical Response with Talimogene Laherparepvec (T-VEC) in Patients with Melanoma Treated in the OPTiM Phase III Clinical Trial. Annals of Surgical Oncology, 2016, 23, 4169-4177.	1.5	236
16	Phase II Randomized Study of Vaccine Treatment of Advanced Prostate Cancer (E7897): A Trial of the Eastern Cooperative Oncology Group. Journal of Clinical Oncology, 2004, 22, 2122-2132.	1.6	226
17	Molecular Pathways: Mechanism of Action for Talimogene Laherparepvec, a New Oncolytic Virus Immunotherapy. Clinical Cancer Research, 2016, 22, 1048-1054.	7.0	226
18	Talimogene Laherparepvec (T-VEC) and Other Oncolytic Viruses for the Treatment of Melanoma. American Journal of Clinical Dermatology, 2017, 18, 1-15.	6.7	215

#	Article	IF	Citations
19	Phase I clinical trial of a recombinant canarypoxvirus (ALVAC) vaccine expressing human carcinoembryonic antigen and the B7.1 co-stimulatory molecule. Cancer Immunology, Immunotherapy, 2000, 49, 504-514.	4.2	195
20	OPTIM trial: a Phase III trial of an oncolytic herpes virus encoding GM-CSF for unresectable stage III or IV melanoma. Future Oncology, 2010, 6, 941-949.	2.4	195
21	Clinical landscape of oncolytic virus research in 2020. , 2020, 8, e001486.		191
22	Vaccination of Metastatic Renal Cancer Patients with MVA-5T4: A Randomized, Double-Blind, Placebo-Controlled Phase III Study. Clinical Cancer Research, 2010, 16, 5539-5547.	7.0	184
23	Serum Vascular Endothelial Growth Factor and Fibronectin Predict Clinical Response to High-Dose Interleukin-2 Therapy. Journal of Clinical Oncology, 2009, 27, 2645-2652.	1.6	167
24	Intratumoral injection of the seasonal flu shot converts immunologically cold tumors to hot and serves as an immunotherapy for cancer. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 1119-1128.	7.1	140
25	Targeting the local tumor microenvironment with vaccinia virus expressing B7.1 for the treatment of melanoma. Journal of Clinical Investigation, 2005, 115, 1903-1912.	8.2	126
26	Consensus nomenclature for CD8⁺T cell phenotypes in cancer. OncoImmunology, 2015, 4, e998538.	4.6	119
27	The lymphoid chemokine CCL21 costimulates naÃ¯ve T cell expansion and Th1 polarization of non-regulatory CD4+ T cells. Cellular Immunology, 2004, 231, 75-84.	3.0	113
28	Combination Chemotherapy and ALVAC-CEA/B7.1 Vaccine in Patients with Metastatic Colorectal Cancer. Clinical Cancer Research, 2008, 14, 4843-4849.	7.0	105
29	Poxvirus-based vaccine therapy for patients with advanced pancreatic cancer. Journal of Translational Medicine, 2007, 5, 60.	4.4	102
30	Clinical development of talimogene laherparepvec (T-VEC): a modified herpes simplex virus type-1â€“derived oncolytic immunotherapy. Expert Review of Anticancer Therapy, 2015, 15, 1389-1403.	2.4	102
31	MEK inhibition enhances oncolytic virus immunotherapy through increased tumor cell killing and T cell activation. Science Translational Medicine, 2018, 10, .	12.4	97
32	Results of a phase I trial of a recombinant vaccinia virus that expresses carcinoembryonic antigen in patients with advanced colorectal cancer. Annals of Surgical Oncology, 1996, 3, 495-500.	1.5	91
33	Optimal Management of Metastatic Melanoma: Current Strategies and Future Directions. American Journal of Clinical Dermatology, 2013, 14, 179-194.	6.7	89
34	Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma. Cancer Immunology, Immunotherapy, 2016, 65, 1533-1544.	4.2	89
35	Development of a new fusion-enhanced oncolytic immunotherapy platform based on herpes simplex virus type 1. , 2019, 7, 214.		86
36	Impact of the CCR5 gene polymorphism on the survival of metastatic melanoma patients receiving immunotherapy. Cancer Immunology, Immunotherapy, 2008, 57, 685-691.	4.2	83

#	Article	IF	Citations
37	Efficacy and safety of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in patients with stage IIIB/C and IVM1a melanoma: subanalysis of the Phase III OPTiM trial. OncoTargets and Therapy, 2016, Volume 9, 7081-7093.	2.0	83
38	Oncolytic virus immunotherapy induces immunogenic cell death and overcomes STING deficiency in melanoma. OncoImmunology, 2019, 8, e1591875.	4.6	78
39	A recombinant vaccinia virus expressing human carcinoembryonic antigen (CEA). International Journal of Cancer, 1991, 48, 900-907.	5.1	73
40	Local Delivery of Vaccinia Virus Expressing Multiple Costimulatory Molecules for the Treatment of Established Tumors. Human Gene Therapy, 2006, 17, 239-244.	2.7	73
41	OPTiM: A randomized phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment (tx) of unresected stage IIIB/C and IV melanoma.. Journal of Clinical Oncology, 2013, 31, LBA9008-LBA9008.	1.6	67
42	The promise of Immuno-oncology: implications for defining the value of cancer treatment. , 2019, 7, 129.		66
43	Phase II trial of Modified Vaccinia Ankara (MVA) virus expressing 5T4 and high dose Interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma. Journal of Translational Medicine, 2009, 7, 2.	4.4	64
44	Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop. , 2019, 7, 131.		64
45	High-dose interleukin-2 (IL-2) for the treatment of melanoma: safety considerations and future directions. Expert Opinion on Drug Safety, 2017, 16, 1347-1357.	2.4	60
46	An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0. , 2018, 6, 44.		59
47	Immune oncology, immune responsiveness and the theory of everything. , 2018, 6, 50.		58
48	Immunotherapy for melanoma. Clinics in Dermatology, 2004, 22, 251-265.	1.6	50
49	Cutaneous head and neck melanoma in OPTiM, a randomized phase 3 trial of talimogene laherparepvec versus granulocyteâ€macrophage colonyâ€stimulating factor for the treatment of unresected stage IIIB/IIIC/IV melanoma. Head and Neck, 2016, 38, 1752-1758.	2.0	49
50	Immunotherapy for Non-melanoma Skin Cancer. Current Oncology Reports, 2021, 23, 125.	4.0	49
51	Immune evasion mechanisms and immune checkpoint inhibition in advanced merkel cell carcinoma. OncoImmunology, 2017, 6, e1338237.	4.6	47
52	Immune system versus tumor: shifting the balance in favor of DCs and effective immunity. Journal of Clinical Investigation, 2004, 113, 664-667.	8.2	47
53	Insertion of interleukin-2 (IL-2) and interleukin-12 (IL-12) genes into vaccinia virus results in effective anti-tumor responses without toxicity. Vaccine, 2002, 20, 1862-1869.	3.8	45
54	Intratumoral Approaches for the Treatment of Melanoma. Cancer Journal (Sudbury, Mass), 2017, 23, 40-47.	2.0	45

#	Article	IF	Citations
55	Clinical Responses of Oncolytic Coxsackievirus A21 (V937) in Patients With Unresectable Melanoma. Journal of Clinical Oncology, 2021, 39, 3829-3838.	1.6	44
56	Final data from CALM: A phase II study of Coxsackievirus A21 (CVA21) oncolytic virus immunotherapy in patients with advanced melanoma.. Journal of Clinical Oncology, 2015, 33, 9030-9030.	1.6	44
57	Primary analysis of a phase 1b multicenter trial to evaluate safety and efficacy of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) in previously untreated, unresected stage IIIB-IV melanoma.. Journal of Clinical Oncology, 2014, 32, 9029-9029.	1.6	43
58	Oncolytic virus therapy for cancer. Oncolytic Virotherapy, 2013, 2, 31.	6.0	42
59	Pox Viral Vaccine Approaches. Seminars in Oncology, 2005, 32, 549-555.	2.2	41
60	The tumour microenvironment and implications for cancer immunotherapy. Expert Opinion on Biological Therapy, 2006, 6, 671-684.	3.1	39
61	Durable response rate as an endpoint in cancer immunotherapy: insights from oncolytic virus clinical trials. , 2017, 5, 72.		37
62	Cancer immunotherapy trials: leading a paradigm shift in drug development. , 2016, 4, 42.		35
63	MVAâ€“5T4-induced immune responses are an early marker of efficacy in renal cancer patients. Cancer Immunology, Immunotherapy, 2011, 60, 829-837.	4.2	34
64	Immunotherapy for Merkel cell carcinoma: a turning point in patient care. , 2018, 6, 23.		34
65	Inhibition of p70 S6 Kinase (S6K1) Activity by A77 1726 and Its Effect on Cell Proliferation and Cell Cycle Progress. Neoplasia, 2014, 16, 824-834.	5.3	32
66	TroVax, a recombinant modified vaccinia Ankara virus encoding 5T4: Lessons learned and future development. Hum Vaccin, 2010, 6, 784-791.	2.4	31
67	IFN-Î» cancer immunotherapy: new kid on the block. Immunotherapy, 2016, 8, 877-888.	2.0	30
68	Vaccines for Melanoma and Renal Cell Carcinoma. Seminars in Oncology, 2012, 39, 263-275.	2.2	29
69	Evaluation of classical clinical endpoints as surrogates for overall survival in patients treated with immune checkpoint blockers: a systematic review and meta-analysis. Journal of Cancer Research and Clinical Oncology, 2018, 144, 2245-2261.	2.5	28
70	Two roads for oncolytic immunotherapy development. , 2019, 7, 26.		28
71	Cytokine Therapy for Cancer. Surgical Oncology Clinics of North America, 2007, 16, 793-818.	1.5	26
72	Management of Metastatic Melanoma in 2018. JAMA Oncology, 2018, 4, 857.	7.1	26

#	Article	IF	Citations
73	Local delivery of recombinant vaccinia virus expressing secondary lymphoid chemokine (SLC) results in a CD4 T-cell dependent antitumor response. Vaccine, 2004, 22, 2894-2903.	3.8	24
74	An Update on the Role of Talimogene Laherparepvec (T-VEC) in the Treatment of Melanoma: Best Practices and Future Directions. American Journal of Clinical Dermatology, 2020, 21, 821-832.	6.7	24
75	Immunotherapy for Nonmelanoma Skin Cancer: Facts and Hopes. Clinical Cancer Research, 2022, 28, 2211-2220.	7.0	23
76	Talimogene Laherparepvec: Moving From First-In-Class to Best-In-Class. Frontiers in Molecular Biosciences, 2022, 9, 834841.	3.5	23
77	Leiomyoma of the breast. , 1996, 62, 62-64.		22
78	Non-oncogenic Acute Viral Infections Disrupt Anti-cancer Responses and Lead to Accelerated Cancer-Specific Host Death. Cell Reports, 2016, 17, 957-965.	6.4	22
79	Nonprogression with avelumab treatment associated with gains in quality of life in metastatic Merkel cell carcinoma. Future Oncology, 2018, 14, 255-266.	2.4	22
80	Unleashing the therapeutic potential of oncolytic viruses. Journal of Clinical Investigation, 2018, 128, 1258-1260.	8.2	22
81	OPTiM: A randomized phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment (tx) of unresected stage IIIB/C and IV melanoma.. Journal of Clinical Oncology, 2013, 31, LBA9008-LBA9008.	1.6	21
82	Immunotherapy for pancreatic cancer: current concepts. Hematology/Oncology Clinics of North America, 2002, 16, 159-197.	2.2	20
83	Critical analysis of an oncolytic herpesvirus encoding granulocyte-macrophage colony stimulating factor for the treatment of malignant melanoma. Oncolytic Virotherapy, 2014, 3, 11.	6.0	19
84	Chronic granulomatous dermatitis induced by talimogene laherparepvec therapy of melanoma metastases. Journal of Cutaneous Pathology, 2018, 45, 48-53.	1.3	19
85	Advancing oncolytic virus therapy by understanding the biology. Nature Reviews Clinical Oncology, 2021, 18, 197-198.	27.6	19
86	Strategies for cancer therapy using carcinoembryonic antigen vaccines. Expert Reviews in Molecular Medicine, 2000, 2, 1-24.	3.9	18
87	Prostate-specific antigen vaccines for prostate cancer. Expert Opinion on Biological Therapy, 2002, 2, 395-408.	3.1	17
88	CALM study: A phase II study of an intratumorally delivered oncolytic immunotherapeutic agent, coxsackievirus A21, in patients with stage IIIc and stage IV malignant melanoma.. Journal of Clinical Oncology, 2014, 32, 3031-3031.	1.6	17
89	Surgical treatment of stage IV melanoma. Clinics in Dermatology, 2004, 22, 240-250.	1.6	15
90	Defining best practices for tissue procurement in immuno-oncology clinical trials: consensus statement from the Society for Immunotherapy of Cancer Surgery Committee. , 2020, 8, e001583.		15

#	Article	IF	Citations
91	Real-world assessment of response to anti-programmed cell death 1 therapy in advanced cutaneous squamous cell carcinoma. Journal of the American Academy of Dermatology, 2021, 85, 1038-1040.	1.2	15
92	TroVax^{Â®}vaccine therapy for renal cell carcinoma. Immunotherapy, 2012, 4, 27-42.	2.0	14
93	Results of a Randomized Phase I Gene Therapy Clinical Trial of Nononcolytic Fowlpox Viruses Encoding T Cell Costimulatory Molecules. Human Gene Therapy, 2014, 25, 452-460.	2.7	14
94	Surgical Management of Melanoma. Cancer Treatment and Research, 2016, 167, 149-179.	0.5	14
95	Current Issues in Cancer Vaccine Development. Clinical Immunology, 1999, 92, 211-223.	3.2	12
96	Perspectives in immunotherapy: meeting report from the Immunotherapy Bridge (29-30 November, 2017,) Tj ETQq0 0 0 rgBT /Overlock		12
97	Viral Vaccines for Cancer Immunotherapy. Hematology/Oncology Clinics of North America, 2006, 20, 661-687.	2.2	11
98	Avelumab and other recent advances in Merkel cell carcinoma. Future Oncology, 2017, 13, 2771-2783.	2.4	11
99	The Value of Cancer Immunotherapy Summit at the 2016 Society for Immunotherapy of Cancer 31st Anniversary Annual Meeting. , 2017, 5, .		11
100	Can Biomarkers Guide Oncolytic Virus Immunotherapy?. Clinical Cancer Research, 2021, 27, 3278-3279.	7.0	11
101	Ipilimumab in metastatic melanoma patients with pre-existing autoimmune disorders.. Journal of Clinical Oncology, 2015, 33, 9019-9019.	1.6	11
102	Clinical Perineural Invasion and Immunotherapy for Head and Neck Cutaneous Squamous Cell Carcinoma. Laryngoscope, 2021, , .	2.0	11
103	COMBINATION INTERLEUKIN-2 AND INTERLEUKIN-12 INDUCES SEVERE GASTROINTESTINAL TOXICITY AND EPITHELIAL CELL APOPTOSIS IN MICE. Cytokine, 2002, 17, 43-52.	3.2	10
104	The role of poxviruses in tumor immunotherapy. Surgery, 2003, 134, 731-737.	1.9	10
105	Long-Term Progression-Free Survival of Patients with Metastatic Melanoma or Renal Cell Carcinoma following High-Dose Interleukin-2. Journal of Investigative Medicine, 2021, 69, 888-892.	1.6	10
106	High-Dose Ipilimumab and High-Dose Interleukin-2 for Patients With Advanced Melanoma. Frontiers in Oncology, 2019, 9, 1483.	2.8	10
107	Clinical features of acute kidney injury in patients receiving dabrafenib and trametinib. Nephrology Dialysis Transplantation, 2022, 37, 507-514.	0.7	10
108	Small bowel obstruction by jejunal enterolith. Surgery, 1997, 121, 229-230.	1.9	9

#	Article	IF	Citations
109	Low-dose interleukin-2 impairs host anti-tumor immunity and inhibits therapeutic responses in a mouse model of melanoma. Cancer Immunology, Immunotherapy, 2017, 66, 9-16.	4.2	9
110	Oncolytic Immunotherapy. Surgical Oncology Clinics of North America, 2019, 28, 419-430.	1.5	8
111	Abstract CT139: Intratumoral oncolytic virus V937 in combination with pembrolizumab (pembro) in patients (pts) with advanced melanoma: Updated results from the phase 1b CAPRA study. Cancer Research, 2021, 81, CT139-CT139.	0.9	8
112	Multi-parametric flow cytometry staining procedure for analyzing tumor-infiltrating immune cells following oncolytic herpes simplex virus immunotherapy in intracranial glioblastoma. Journal of Biological Methods, 2019, 6, e112.	0.6	8
113	CALM study: A phase II study of intratumoral coxsackievirus A21 in patients with stage IIIc and stage IV malignant melanoma.. Journal of Clinical Oncology, 2013, 31, TPS3128-TPS3128.	1.6	7
114	Chemokines and Cancer. Cancer Investigation, 2002, 20, 825-834.	1.3	6
115	Manipulating the Local Tumor Microenvironment with Poxviruses Expressing Costimulatory Molecules. Annals of the New York Academy of Sciences, 2005, 1062, 41-50.	3.8	6
116	Melanoma as a model for precision medicine in oncology. Lancet Oncology, The, 2014, 15, 251-253.	10.7	6
117	Rational Combination Immunotherapy: Understand the Biology. Cancer Immunology Research, 2017, 5, 355-356.	3.4	5
118	Panniculitis after vaccination against CEA and MUC1 in a patient with pancreatic cancer. Lancet Oncology, The, 2005, 6, 62-63.	10.7	5
119	422â€...An open-label, multicenter, phase 1/2 clinical trial of RP1, an enhanced potency oncolytic HSV, combined with nivolumab: updated results from the skin cancer cohorts. , 2020, , .		5
120	Innovations and strategies for the development of anticancer vaccines. Expert Opinion on Pharmacotherapy, 2000, 1, 603-614.	1.8	4
121	Generation and validation of recombinant herpes simplex type 1 viruses (HSV-1) using CRISPR/Cas9 genetic disruption. Methods in Enzymology, 2020, 635, 167-184.	1.0	4
122	Gene Therapy for Antitumor Vaccination. Methods in Molecular Biology, 2009, 542, 515-527.	0.9	4
123	High-dose (HD) IL-2 for metastatic renal cell carcinoma (mRCC) in the targeted therapy era: Extension of OS benefits beyond complete response (CR) and partial response (PR).. Journal of Clinical Oncology, 2014, 32, 4523-4523.	1.6	4
124	Combination Immunotherapy for Melanoma. JAMA Oncology, 2015, 1, 387.	7.1	3
125	Avelumab Immunotherapy: Management of Adverse Events Associated With New Treatment for Merkel Cell Carcinoma. , 2019, 23, E1-E9.		3
126	Defining current gaps in quality measures for cancer immunotherapy: consensus report from the Society for Immunotherapy of Cancer (SITC) 2019 Quality Summit. , 2020, 8, e000112.		3

#	Article	IF	Citations
127	Diagnostic yield of staging brain magnetic resonance imaging is low in Merkel cell carcinoma: A single-institution cohort study. Journal of the American Academy of Dermatology, 2022, 87, 434-435.	1.2	3
128	Safety and efficacy of ipilimumab in melanoma patients who received prior immunotherapy on phase III study MDX010-020.. Journal of Clinical Oncology, 2013, 31, 9050-9050.	1.6	3
129	Improved median overall survival (OS) in patients with metastatic melanoma (mM) treated with high-dose (HD) IL-2: Analysis of the PROCLAIM 2007-2012 national registry.. Journal of Clinical Oncology, 2014, 32, 9054-9054.	1.6	3
130	High dose (HD) IL-2 for metastatic renal cell carcinoma (mRCC) in the targeted therapy era: Extension of OS benefits beyond complete response (CR) and partial response (PR).. Journal of Clinical Oncology, 2015, 33, 423-423.	1.6	3
131	421â€...Initial results of a phase 1 trial of RP2, a first in class, enhanced potency, anti-CTLA-4 antibody expressing, oncolytic HSV as single agent and combined with nivolumab in patients with solid tumors. , 2020, , .		3
132	An update on TroVax® for the treatment of progressive castration-resistant prostate cancer. OncoTargets and Therapy, 2011, 4, 33.	2.0	2
133	Introduction on Cancer Immunology and Immunotherapy. , 2015, , 1-8.		2
134	OPTiM: A randomized phase III trial to evaluate the efficacy and safety of talimogene laherparepvec (T-VEC) compared with subcutaneously (sc) administered GM-CSF for the treatment (tx) of unresectable stage IIIb, IIIc, and IV melanoma.. Journal of Clinical Oncology, 2012, 30, TPS8604-TPS8604.	1.6	2
135	High-dose interleukin-2 registry, PROCLAIM: Modern data on toxicities and outcomes.. Journal of Clinical Oncology, 2014, 32, 430-430.	1.6	2
136	Dynamics of tumor response in advanced melanoma patients treated with Coxsackievirus A21.. Journal of Clinical Oncology, 2016, 34, 9553-9553.	1.6	2
137	A Prospective Analysis of High-Dose Interleukin-2 (HD IL-2) following PD-1 inhibitor therapy in patients with metastatic melanoma and renal cell carcinoma.. Journal of Clinical Oncology, 2016, 34, e21006-e21006.	1.6	2
138	TNFâ€Î±â€induced activation of RhoA/Rho kinase pathway in human pulmonary microvascular endothelial cells. FASEB Journal, 2007, 21, A1201.	0.5	2
139	Synthetic biology: at the crossroads of genetic engineering and human therapeuticsâ€"a Keystone Symposia report. Annals of the New York Academy of Sciences, 2021, , .	3.8	2
140	Cytokines in the Treatment of Cancer. , 2013, , 173-210.		1
141	Triple threat to cancer: rationale for combining oncolytic viruses, MEK inhibitors, and immune checkpoint blockade. OncoImmunology, 2019, 8, e1571390.	4.6	1
142	Durability of responses in patients with metastatic renal cell carcinoma treated with high-dose interleukin-2 (HD IL-2).. Journal of Clinical Oncology, 2016, 34, 511-511.	1.6	1
143	Overall survival (OS) by clinical risk category for high dose interleukin-2 (HD IL-2) treated metastatic renal cell cancer (RCC): Data from PROCLAIM.. Journal of Clinical Oncology, 2018, 36, 4578-4578.	1.6	1
144	Columbia University. Lancet Oncology, The, 2005, 6, 750.	10.7	0

#	Article	IF	Citations
145	DNA Vaccines for Cancer Immunotherapy. , 2006, , 87-114.		0
146	Modified Oncolytic Herpesviruses for Gene Therapy of Cancer. , 2014, , 213-223.		0
147	Finding gold in tumour immunotherapy. Lancet Oncology, The, 2017, 18, e561.	10.7	0
148	Can Surgeons Expand the Role of Oncolytic Viruses for Cancer Treatment? An Editorial Comment on â€œFighting Fire with Fire: Oncolytic Virotherapy in Thoracic Malignanciesâ€• Annals of Surgical Oncology, 2021, 28, 2432-2433.	1.5	0
149	DNA Vaccines. , 2004, , 225-248.		0
150	Modulating the Tumor Microenvironment. , 2012, , 353-369.		0
151	Effect of the novel therapeutic cancer vaccine formulation DPX-0907 on multifunctional T-cell responses in ovarian, breast, and prostate cancer patients.. Journal of Clinical Oncology, 2012, 30, 2588-2588.	1.6	0
152	Interleukin 2. , 2013, , 1-12.		0
153	CTLA-4. , 2013, , 1-14.		0
154	An exploratory study of the biologic effects of nivolumab (Anti-PD-1; BMS-936558; ONO-4538) treatment in patients (pts) with advanced (unresectable or metastatic) melanoma (MEL).. Journal of Clinical Oncology, 2013, 31, TPS3114-TPS3114.	1.6	0
155	The Use of Oncolytic Herpesvirus for the Treatment of Cancer. , 2014, , 329-345.		0
156	A Phase II multicenter trial to evaluate combination ipilimumab and high-dose IL-2 in patients with unresectable stage III and IV melanoma.. Journal of Clinical Oncology, 2015, 33, TPS3095-TPS3095.	1.6	0
157	Interleukin-12. , 2016, , 1-15.		0
158	High Dose Interleukin-2 Therapy. , 2007, , 431-452.		0
159	Combination Cytokine Therapy. , 2007, , 373-398.		0